---
layout: default
title: Naltrexone
parent: AI Predictions (L5)
nav_order: 406
evidence_level: L5
indication_count: 10
---

# Naltrexone
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Naltrexone: From Unregistered Indication to Hypervitaminosis (Low-Confidence Signal)

## One-Sentence Summary

Naltrexone (DrugBank DB00704) currently has no recorded marketing authorization or approved indication in this jurisdiction, and detailed mechanism-of-action data is not yet available in this evidence pack. The TxGNN model's top-ranked prediction is **Hypervitaminosis**, but this association is supported by **0 clinical trials** and **0 publications**, and the internal mechanistic review flags it as likely model noise rather than a biologically plausible signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no marketing authorizations on file for this drug in this jurisdiction |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 98.66% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the information provided, Naltrexone's original approved indication(s) are also not recorded in this evidence pack — the drug is not currently marketed in this jurisdiction (0 authorizations on file).

Naltrexone is pharmacologically known as an opioid receptor antagonist. However, for the top-ranked prediction, **Hypervitaminosis** (vitamin overdose/toxicity), the evidence pack's own rationale explicitly states there is *"no plausible mechanism: opioid receptor antagonism has no known intersection with vitamin-overdose metabolic pathways"*, and classifies this as likely **TxGNN embedding noise** rather than a genuine signal.

Reviewing the remaining top-10 predictions reinforces this concern: most candidates (e.g., proximal 16p11.2 microdeletion syndrome, obsolete hypertelorism, frontorhiny, DECR deficiency leukodystrophy, myxomatous mitral valve prolapse, bridged sella turcica, nonopposable triphalangeal thumb) have no mechanistic rationale connecting them to opioid receptor pharmacology, and several are rare congenital/structural conditions or even obsolete disease terms. The one candidate with an evidence-based literature trail — **restless legs syndrome (rank 5, L4)** — is itself mechanistically ambiguous: the cited literature suggests endogenous opioid *deficiency* may underlie RLS pathophysiology, implying an opioid *agonist* (not an antagonist like naltrexone) would be the more logical therapeutic direction. As such, none of the top-10 predictions in this pack currently present a mechanistically coherent, evidence-supported repurposing case.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

*(Note: literature evidence exists for the rank-5 candidate, restless legs syndrome, but not for the top-ranked prediction, hypervitaminosis, shown above. See Conclusion for further discussion.)*

---

## EU Market Information

No marketing authorizations are currently on file for this drug in this jurisdiction (0 licenses; market status: Not Marketed).

---

## Safety Considerations

Please refer to the SmPC for safety information.

*(Drug-level safety data — including TFDA/regulatory label warnings and contraindications — is marked as a **Blocking** data gap in this evidence pack and has not yet been retrieved.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Hypervitaminosis) has no clinical trial or literature support and is explicitly flagged by the internal mechanistic review as likely model noise, with no plausible biological link to opioid receptor antagonism. In addition, two drug-level data gaps are marked **Blocking**/**High** severity — missing mechanism-of-action data and missing regulatory label warnings/contraindications — meaning this candidate has not yet cleared the initial safety screening stage (S1).

**To proceed, the following is needed:**
- Retrieve Naltrexone's mechanism-of-action data via the DrugBank API (DG002)
- Obtain the applicable regulatory label (warnings/contraindications) to complete S1 safety screening (DG001, Blocking)
- If pursuing further evaluation, prioritize the restless legs syndrome candidate (rank 5, L4, 5 supporting publications) over Hypervitaminosis, while resolving the antagonist-vs-agonist mechanistic conflict noted above
- Independently re-validate the top-10 prediction list for mechanistic plausibility before committing further review resources, given multiple candidates in this batch appear to be low-confidence embedding artifacts (including one obsolete disease term)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

